Editas Medication stated Thursday afternoon it’s going to lay off 65% of its team of workers — round 180 staff — because it cabinets its lead gene-editing program for sickle cellular illness and shifts focal point.
The cuts come amid a protracted monetary downturn for the gene-editing box, as valuations have plummeted and layoffs have transform popular. Editas already laid off team of workers as a part of a restructuring in 2023. Its inventory has fallen 81% this 12 months.
Editas introduced with immense fanfare a decade in the past, as one of the vital first 3 firms based across the promise of CRISPR genome enhancing. But it surely struggled on execution, opting for to head after hard-to-reach illnesses, and it noticed important turnover as early methods failed or stagnated.
STAT+ Unique Tale
Have already got an account? Log in
This text is unique to STAT+ subscribers
Liberate this newsletter — plus day by day protection and research of the biotech sector — via subscribing to STAT+.
Have already got an account? Log in
Particular person plans
Crew plans
View All Plans
To learn the remainder of this tale subscribe to STAT+.
Subscribe
